Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
This study has been completed.
Sponsor:
University Medicine Greifswald
Collaborator:
RIEMSER Arzneimittel GmbH
Information provided by (Responsible Party):
University Medicine Greifswald
ClinicalTrials.gov Identifier:
NCT01429090
First received: September 1, 2011
Last updated: September 2, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of the study is:
•To describe extent and rate of absorption of methantheline after single oral dose administration of Vagantin® coated tablets (Test) in comparison to a methantheline bromide solution (Reference)
The secondary objectives of the study are:
- To determine elimination the half-life of methantheline bromide
- To describe the effects of Test and Reference on salivation, accommodation, pupil response, blood pressure and heart rate
- to assess frequency and intensity of adverse drug reactions
| Condition | Intervention | Phase |
|---|---|---|
|
Neurogenic Bladder |
Procedure: blood sampling Drug: Vagantin® Drug: methantheline solution Procedure: Measurement of salivation Procedure: Measurement of accommodation Procedure: Pupillometry |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
Further study details as provided by University Medicine Greifswald:
Primary Outcome Measures:
- area under the curve (AUC0-∞) [ Time Frame: 0-16 h plasma concentration-time profile of methantheline after single oral administration ] [ Designated as safety issue: No ]AUC0-∞ was assessed by the trapezoidal formula up to the last sampling time with a concentration above the limit of quantitation (AUC0-), and was extrapolated to infinity using standard techniques
- maximal plasma concentration (Cmax) [ Time Frame: 0-16 h plasma concentration-time profile of methantheline after single oral administration ] [ Designated as safety issue: No ]Cmax was obtained directly from the measured concentration-time curves
Secondary Outcome Measures:
- time of maximal plasma concentration (tmax) [ Time Frame: 0-16 h plasma concentration-time profile of methantheline after single oral administration ] [ Designated as safety issue: No ]tmax was obtained directly from the measured concentration-time curves
- terminal half-life (t½) [ Time Frame: 0-16 h plasma concentration-time profile of methantheline after single oral administration ]Half-life (t½) was evaluated by non-linear regression of the terminal slope
- volume of salivary gland secretion [ Time Frame: before and 0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication ] [ Designated as safety issue: No ]Volume of salivary gland secretion will be measured by chewing a 5 x 5 cm piece of PARAFILM "M"® (American Can Company, UK) for 5 min. Saliva will be collected in glass tubes the volume of which will be measured be weighing
- Measurement of accommodation [ Time Frame: before and 0, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication ] [ Designated as safety issue: No ]Accommodation will be measured with the optometer according to Schober (Velhagen 1972)
- Pupil function [ Time Frame: before and 0, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication ] [ Designated as safety issue: No ]Pupil function will be assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data will be obtained: pupil diameter, response to defined flash stimuli
| Enrollment: | 12 |
| Study Start Date: | October 1999 |
| Study Completion Date: | January 2000 |
| Primary Completion Date: | November 1999 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Test
Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
|
Procedure: blood sampling
blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
Drug: Vagantin®
administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
Procedure: Measurement of salivation
Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM "M"® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing
Procedure: Measurement of accommodation
Accommodation was measured with the optometer according to Schober (Velhagen 1972)
Procedure: Pupillometry
Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
|
|
Active Comparator: Reference
Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
|
Procedure: blood sampling
blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
Drug: methantheline solution
administration 100 ml methantheline solution (100 mg methantheline bromide)
Procedure: Measurement of salivation
Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM "M"® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing
Procedure: Measurement of accommodation
Accommodation was measured with the optometer according to Schober (Velhagen 1972)
Procedure: Pupillometry
Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
|
Detailed Description:
The quarternary anticholinergic compound methantheline bromide (diethyl-methyl [2-(9 xanthenyl carbonyloxy) ethyl] ammonium bromide) is marketed to treat neurogenic bladder instability. In comparison with atropine, it influences the parasympathetic nervous transmission more by ganglionic rather than peripheral muscarinic receptor blockade. Clinical effects after single therapeutic doses of 50-100 mg last for about 6 hours which is longer than after atropine. The drug relaxes smooth muscles of the gastrointestinal and urogenital tract. Furthermore, it inhibits bronchial, salivary and sweat glands secretion, lowers the production of gastric juice and disturbs accommodation.
There are no data available on the pharmacokinetic properties of methantheline in man. However, 25-50 mg intravenous methantheline seem to be equivalent to 50-100 mg p.o. with regard to the pharmacodynamic effects [Stille 1988].
Vagantin® is marketed as coated tablets containing 50 mg methantheline bromide. Because of the particular properties of methantheline (narrow therapeutic range, obviously erratic, incomplete and irregular absorption) and because of the national and international recommendations concerning the registration of drugs, Vagantin® must be evaluated with regard to its pharmacokinetic properties at least relative to a non-formulated form.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- age: 18 - 45 years
- sex: male and female
- ethnic origin: Caucasian
- body weight: ±20 % of normal weight (Broca)
- good health as evidenced by the results of the clinical examination and the laboratory check-up which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state
- written informed consent
Exclusion Criteria:
- known hypersensitivity to the investigational products or to their adjuvants
- pollakisurie of cardial and renal reasons
- megacolon
- atonia of the gastrointestinal tract
- atonia or hypotonia of the urinary bladder
- tachycardiac arrhythmia
- subvesical bladder obstruction, especially benign prostatic hypertrophy
- narrow angle glaucoma
- glasses or contact lenses
- history of gastrointestinal diseases (except appendectomy)
- history of renal and/or hepatic diseases
- any disease known to modify absorption, metabolism or excretion of the drug under investigation
- liability to orthostatic dysregulation, faintings, or blackouts
- alcohol consumption more than 40 g/day
- smokers of more than 10 cigarettes per day
- special or uniform nutritional habits, e.g. vegetarians or under-caloric diet
- less than 14 days after last acute disease
- less than 14 days after last systemic or local drug administration or 10 times the half life of the respective drug (except hormonal contraceptives)
- blood donation within the last two months
- blocking period due to another clinical study with investigational products; however at least 4 weeks after the end of the study or 10 times the half life of the respective drug
- lack of willingness or inability to co-operate adequately
- HIV and HBV and drug screening positive or not performed (in case of a positive HIV-test, the volunteers must be informed by a physician in a personal conversation)
- lactation and pregnancy test positive or not performed
Contacts and Locations More Information
No publications provided by University Medicine Greifswald
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University Medicine Greifswald |
| ClinicalTrials.gov Identifier: | NCT01429090 History of Changes |
| Other Study ID Numbers: | BAMB0199 |
| Study First Received: | September 1, 2011 |
| Last Updated: | September 2, 2011 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by University Medicine Greifswald:
|
Pharmacokinetics Accommodation, Ocular Reflex, Pupillary Salivation |
Additional relevant MeSH terms:
|
Urinary Bladder, Neurogenic Neurologic Manifestations Nervous System Diseases Urinary Bladder Diseases Urologic Diseases Signs and Symptoms Bromides Methantheline Anticonvulsants |
Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013